Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2420658 | 0.98 | OPRM1 (0.53) | OPRM1OPRK1OPRL1OPRD1HTR2A | |
| SCHEMBL2423427 | 0.89 | HTR2A (0.53) | OPRM1OPRK1OPRL1OPRD1HTR2A | |
| Hydrochloric Acid SCHEMBL23705827 | 0.87 | HTR2A (0.52) | OPRM1OPRK1OPRL1OPRD1HTR2A | |
| SCHEMBL13876257 | 0.85 | OPRM1 (0.59) | OPRM1OPRK1OPRL1OPRD1HSD11B1 | |
| SCHEMBL14899046 | 0.81 | OPRM1 (0.56) | OPRM1OPRK1OPRL1OPRD1HSD11B1 | |
| SCHEMBL10821867 | 0.81 | OPRM1 (0.56) | OPRM1OPRK1OPRL1OPRD1HSD11B1 | |
| SCHEMBL186851 | 0.81 | DRD2 (0.55) | OPRM1OPRK1OPRL1OPRD1SIGMAR1 | |
| SCHEMBL28818447 | 0.81 | OPRM1 (0.35) | OPRM1OPRK1OPRL1OPRD1SIGMAR1 | |
| SCHEMBL19458949 | 0.81 | MMP2 (0.35) | OPRM1OPRK1OPRL1OPRD1TACR1 | |
| SCHEMBL8166976 | 0.80 | OPRM1 (0.55) | OPRM1HTR2ATACR1AKT2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| EP-2477983-B1 | (4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE | UNIV EDINBURGH (GB) | 2015-04-15 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
| EP-0937715-B1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-6884868-B1 | Cyclic hexapeptides having antibiotic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| US-6355642-B1 | PSYCHOLOGICAL DISORDERS AND BRAIN DISORDERS | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| EP-1173472-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064927-A1 | CYCLIC HEXAPEPTIDES HAVING ANTIBIOTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | WO | disclosed |
| EP-0937715-A1 | TETRAHYDROBENZINDOLE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1999-08-25 | — | — | EP | disclosed |
| US-4061760-A | Method for using 3-substituted-5-phenyl-5-pyridyl hydantoins as antiarrhythmic agents | MILES LABORATORIES, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-3994904-A | 3-Substituted -5-phenyl-5-pyridyl hydantoins | MILES LABORATORIES, INC. (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | OPRM1 4/4885OPRK1 1/4885OPRL1 3/4885 |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | AVPR1A, AVPR2, OXTR | OPRM1 34/4885OPRK1 11/4885OPRL1 8/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | OPRM1 85/4885OPRK1 13/4885OPRL1 10/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | OPRM1 1787/4885OPRK1 697/4885OPRL1 1996/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | OPRM1 1787/4885OPRK1 697/4885OPRL1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.